# 177LuPSMA in Renal Cell Carcinoma

> **NCT06964958** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 24 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Kidney Cancer

## Interventions

- **DRUG:** 177Lu-PSMA-617

## Key facts

- **NCT ID:** NCT06964958
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06964958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06964958, "177LuPSMA in Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06964958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*